Antibe Therapeutics Inc. announce the initiation of the pharmacokinetic/pharmacodynamic (?PK/PD?) study of otenaproxesul?s faster-absorbing formulation for acute pain. The study is designed to inform the doses and confirm safety in preparation for the Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study will involve 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul.

Subjects will remain in-clinic for the duration of their treatment. Expected in November, the study data will also advance Antibe?s exploration of potential treatment regimens for chronic pain.